The molecular basis of lung cancer: molecular abnormalities and therapeutic implications

by Massion, Pierre P, Carbone, David P
Published 2003

Cancer therapy by resuscitating Notch immune surveillance

by Shanker, Anil, Dudimah, Duafalia F, Pellom, Samuel T, Uzhachenko, Roman V, Carbone, David P, Dikov, Mikhail M
Published 2014

Cancer therapy by restoration of immune Notch

by Shanker, Anil, Dudimah, Duafalia F, Uzhachenko, Roman V, Biktasova, Asel K, Carbone, David P, Dikov, Mikhail M
Published 2013

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT

by Kaufman, Jacob M., Amann, Joseph M., Park, Kyungho, Arasada, Rajeswara Rao, Li, Haotian, Shyr, Yu, Carbone, David P.
Published 2014

Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk

by Thounaojam, Menaka C., Dudimah, Duafalia F., Pellom, Samuel T., Uzhachenko, Roman V., Carbone, David P., Dikov, Mikhail M., Shanker, Anil
Published 2015

LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small cell lung cancer (NSCLC) cells

by Whang, Young Mi, Park, Serk In, Trenary, Irina A., Egnatchik, Robert A., Fessel, Joshua P., Kaufman, Jacob M., Carbone, David P., Young, Jamey D.
Published 2015

Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency

by Araujo, Luiz H., Timmers, Cynthia, Shilo, Konstantin, Zhao, Weiqiang, Zhang, Jianying, Yu, Lianbo, Natarajan, Thanemozhi G., Miller, Clinton J., Yilmaz, Ayse Selen, Liu, Tom, Amann, Joseph, Lapa e Silva, José Roberto, Ferreira, Carlos Gil, Carbone, David P.
Published 2015

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small...

by Maitland, Michael L, Levine, Matthew R, Lacouture, Mario E, Wroblewski, Kristen E, Chung, Christine H, Gordon, Ilyssa O, Szeto, Livia, Ratko, Gail, Soltani, Keyoumars, Kozloff, Mark F, Hoffman, Philip C, Salgia, Ravi, Carbone, David P, Karrison, Theodore G, Vokes, Everett E
Published 2014

Defining a standard set of patient-centred outcomes for lung cancer

by Mak, Kimberley S., van Bommel, Annelotte C.M., Stowell, Caleb, Abrahm, Janet L., Baker, Matthew, Baldotto, Clarissa S., Baldwin, David R., Borthwick, Diana, Carbone, David P., Chen, Aileen B., Fox, Jesme, Haswell, Tom, Koczywas, Marianna, Kozower, Benjamin D., Mehran, Reza J., Schramel, Franz M., Senan, Suresh, Stirling, Robert G., van Meerbeeck, Jan P., Wouters, Michel W.J.M., Peake, Michael D.
Published 2016

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a...

by Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Published 2016

PDL1 Regulation by p53 via miR-34

by Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J., Ye, Yuping, Araujo, Luiz, Carbone, David P., Shilo, Konstantin, Giri, Dipak K, Kelnar, Kevin, Martin, Desiree, Komaki, Ritsuko, Gomez, Daniel R., Krishnan, Sunil, Calin, George A., Bader, Andreas G., Welsh, James W.
Published 2015